PubMed:15266215 / 1634-1961 JSONTXT

{"project":"LitCoin-entities","denotations":[{"id":"1023","span":{"begin":117,"end":127},"obj":"ChemicalEntity"},{"id":"1024","span":{"begin":184,"end":194},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1025","span":{"begin":227,"end":233},"obj":"ChemicalEntity"},{"id":"1026","span":{"begin":248,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1027","span":{"begin":267,"end":287},"obj":"DiseaseOrPhenotypicFeature"},{"id":"1028","span":{"begin":288,"end":296},"obj":"OrganismTaxon"}],"attributes":[{"id":"A40","pred":"db_id","subj":"1023","obj":"MESH:C406224"},{"id":"A41","pred":"db_id","subj":"1024","obj":"MESH:D013927"},{"id":"A42","pred":"db_id","subj":"1025","obj":"MESH:D000894"},{"id":"A43","pred":"db_id","subj":"1026","obj":"MESH:D010003"},{"id":"A44","pred":"db_id","subj":"1027","obj":"MESH:D001172"},{"id":"A45","pred":"db_id","subj":"1028","obj":"NCBITaxon:9606"}],"namespaces":[{"prefix":"_base","uri":"https://w3id.org/biolink/vocab/"},{"prefix":"MESH","uri":"http://id.nlm.nih.gov/mesh/"},{"prefix":"NCBITaxon","uri":"https://www.ncbi.nlm.nih.gov/Taxonomy/Browser/wwwtax.cgi?id="},{"prefix":"NCBIGene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"OMIM","uri":"https://www.omim.org/entry/"},{"prefix":"DBSNP","uri":"https://www.ncbi.nlm.nih.gov/snp/"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-sentences","denotations":[{"id":"T10","span":{"begin":0,"end":327},"obj":"Sentence"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin_Mondo","denotations":[{"id":"T5","span":{"begin":248,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T6","span":{"begin":267,"end":287},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A5","pred":"mondo_id","subj":"T5","obj":"0005178"},{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0008383"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-GeneOrGeneProduct-v0","denotations":[{"id":"T23","span":{"begin":24,"end":28},"obj":"GeneOrGeneProduct"},{"id":"T24","span":{"begin":57,"end":62},"obj":"GeneOrGeneProduct"},{"id":"T25","span":{"begin":66,"end":68},"obj":"GeneOrGeneProduct"},{"id":"T26","span":{"begin":98,"end":103},"obj":"GeneOrGeneProduct"},{"id":"T27","span":{"begin":107,"end":109},"obj":"GeneOrGeneProduct"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-GeneOrGeneProduct-v2","denotations":[{"id":"T12","span":{"begin":24,"end":28},"obj":"GeneOrGeneProduct"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-Disease-MeSH","denotations":[{"id":"T6","span":{"begin":248,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":267,"end":287},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A6","pred":"originalLabel","subj":"T6","obj":"D010003"},{"id":"A7","pred":"originalLabel","subj":"T7","obj":"D001172"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin_Mondo_095","denotations":[{"id":"T6","span":{"begin":248,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T7","span":{"begin":267,"end":287},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A6","pred":"mondo_id","subj":"T6","obj":"0005178"},{"id":"A7","pred":"mondo_id","subj":"T7","obj":"0008383"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-MeSH-Disease-2","denotations":[{"id":"T13","span":{"begin":184,"end":194},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":248,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":267,"end":287},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A13","pred":"ID:","subj":"T13","obj":"DISEASE"},{"id":"A14","pred":"ID:","subj":"T14","obj":"D010003"},{"id":"A15","pred":"ID:","subj":"T15","obj":"D001172"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-NCBITaxon-2","denotations":[{"id":"T4","span":{"begin":288,"end":296},"obj":"OrganismTaxon"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-MONDO_bioort2019","denotations":[{"id":"T13","span":{"begin":184,"end":194},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T14","span":{"begin":248,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T15","span":{"begin":267,"end":287},"obj":"DiseaseOrPhenotypicFeature"}],"attributes":[{"id":"A13","pred":"#label","subj":"T13","obj":"DISEASE"},{"id":"A14","pred":"#label","subj":"T14","obj":"D010003"},{"id":"A15","pred":"#label","subj":"T15","obj":"D001172"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-Chemical-MeSH-CHEBI","denotations":[{"id":"T38","span":{"begin":117,"end":127},"obj":"ChemicalEntity"},{"id":"T40","span":{"begin":227,"end":233},"obj":"ChemicalEntity"}],"attributes":[{"id":"A38","pred":"ID:","subj":"T38","obj":"C406224"},{"id":"A39","pred":"ID:","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_63634"},{"id":"A40","pred":"ID:","subj":"T40","obj":"ChemicalEntity"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}

{"project":"LitCoin-training-merged","denotations":[{"id":"T40","span":{"begin":227,"end":233},"obj":"ChemicalEntity"},{"id":"T38","span":{"begin":117,"end":127},"obj":"ChemicalEntity"},{"id":"T54125","span":{"begin":267,"end":287},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T51976","span":{"begin":248,"end":262},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T13","span":{"begin":184,"end":194},"obj":"DiseaseOrPhenotypicFeature"},{"id":"T38613","span":{"begin":288,"end":296},"obj":"OrganismTaxon"}],"attributes":[{"id":"A40","pred":"ID:","subj":"T40","obj":"ChemicalEntity"},{"id":"A39","pred":"ID:","subj":"T38","obj":"http://purl.obolibrary.org/obo/CHEBI_63634"},{"id":"A38","pred":"ID:","subj":"T38","obj":"C406224"},{"id":"A40690","pred":"#label","subj":"T54125","obj":"D001172"},{"id":"A30362","pred":"#label","subj":"T51976","obj":"D010003"},{"id":"A80171","pred":"#label","subj":"T13","obj":"DISEASE"}],"text":"Short- and intermediate-term treatment with therapeutic (10 or 20 mg daily) and supratherapeutic (40 or 80 mg daily) valdecoxib doses was not associated with an increased incidence of thrombotic events relative to nonselective NSAIDs or placebo in osteoarthritis and rheumatoid arthritis patients in controlled clinical trials."}